A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2016
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms TRIPLE NEGATIVE
- 07 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017.
- 06 Dec 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2017.